A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms.
Clin Cancer Res
; 29(4): 731-741, 2023 02 16.
Article
in En
| MEDLINE
| ID: mdl-36255391
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Neuroendocrine Tumors
/
Lung Neoplasms
Limits:
Humans
Language:
En
Journal:
Clin Cancer Res
Journal subject:
NEOPLASIAS
Year:
2023
Type:
Article